Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Novel Nilotinib Tablet Formulation: Pharmacokinetic Characterization and Effects of Food

Michael J. Mauro, Jerald P. Radich, Paras Jain, David Sequeira, Dan Douer

Blood (2024) 144 (Supplement 1): 5799.

https://doi.org/10.1182/blood-2024-194406

Published: 2024

Journal Articles

Updated Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Peg-Asparaginase in the Era of Novel Agents

Vincent Louie Louie Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11702–11704.

https://doi.org/10.1182/blood-2022-164836

Published: 2022

Journal Articles

Updated Comparison of Outcomes in Hispanic and Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen in the Era of Novel Agents

Vincent Louie Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11685–11687.

https://doi.org/10.1182/blood-2022-167684

Published: 2022

Journal Articles

Updated Outcomes of the University of Southern California (USC) ALL Frontline Regimen (based on CCG-1882) after Protocol Modification in the Era of Novel Agents in Ph-Negative ALL Patients

Vincent Louie Ramos Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Maria E. Vergara-Lluri, Karrune Woan, Eric Tam, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11668–11670.

https://doi.org/10.1182/blood-2022-167512

Published: 2022

Journal Articles

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Chezi Ganzel, Kevin Roopcharan, Zhuoxin Sun, Jacob M. Rowe, Hugo F Fernandez, Elisabeth M. Paietta, Selina M. Luger, Hillard M Lazarus, Larry D Cripe, Dan Douer, Peter H. Wiernik, Martin S. Tallman, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 690.

https://doi.org/10.1182/blood-2021-149208

Published: 2021

Journal Articles

An Update on Outcomes Using the USC ALL Frontline Regimen (based on CCG-1882) after Further Modification of Protocol in the Era of Novel Agents in Ph-Negative ALL Patients; A Retrospective Study

Vincent Louie Mendiola, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Maria E. Vergara-Lluri, Karrune Woan, Eric Tam, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2021) 138 (Supplement 1): 3362.

https://doi.org/10.1182/blood-2021-147124

Published: 2021

Journal Articles

Superior Outcomes in Hispanic Patients Compared to Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen for Newly Diagnosed ALL Patients in the Era of Novel Agents; A Retrospective Study

Vincent Louie Ramos Mendiola, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2021) 138 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2021-150116

Published: 2021

Journal Articles

Research and Care Networks in Acute Leukemia As a Model for Global Healthcare Collaboration

Martin R Guscott, Stacy L Cooper, Poonam Bagai, Archie Bleyer, Randal K Buddington, Dan Douer, Tina B Chong, Ryan R Combs, Jennifer L Hylton, Gabriela Ines-Villanueva, Jennifer A Lowe, Rishabh Pandey, Aman N Patel, Scott C Howard

Blood (2021) 138 (Supplement 1): 4966.

https://doi.org/10.1182/blood-2021-147876

Published: 2021

Journal Articles

Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Pegaspargase in the Era of Novel Agents; A Retrospective Study

Vincent Louie Ramos Mendiola, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2021) 138 (Supplement 1): 4372.

https://doi.org/10.1182/blood-2021-150135

Published: 2021

Journal Articles

How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia

Ibrahim Aldoss, Dan Douer

Blood (2020) 135 (13): 987–995.

https://doi.org/10.1182/blood.2019002477

Published: 2020

Journal Articles

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Mark Blaine Geyer, MD, Ellen K. Ritchie, MD, Arati V. Rao, MD, M. Isabella Cazacu, Shreya Vemuri, Martin S. Tallman, MD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 4013.

https://doi.org/10.1182/blood-2018-99-115486

Published: 2018

Journal Articles

Acute Lymphocytic Leukemia in the Latin American Population

Elisa Quiroz, MD, Rebecca Nelson, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD, Thomas Slavin, MD, Guido Marcucci, Eduardo Magalhães Rego, MD PhD, Dan Douer, MD

Blood (2018) 132 (Supplement 1): 5282.

https://doi.org/10.1182/blood-2018-99-120079

Published: 2018

Journal Articles

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Mark Blaine Geyer, MD, Patrick W. Burke, MD, Amber C. King, PharmD, BCOP, Michael J. Mauro, MD, Martin S. Tallman, MD, Ross L. Levine, MD, Charles J. Sherr, MD PhD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2018-99-110537

Published: 2018

Journal Articles

Clinical, Cytogenetic and Immunophenotype Distribution of Adult Acute Lymphoblastic Leukemia Among Latinos — a Report from a Large Single Institution Cohort in Southern California

Elisa Quiroz, MD, Rebecca Nelson, MD, Vinod A. Pullarkat, MD, Ibrahim Aldoss, Thomas Slavin, MD, Eduardo Magalhães Rego, MD PhD, Guido Marcucci, Dan Douer, MD

Blood (2018) 132 (Supplement 1): 2816.

https://doi.org/10.1182/blood-2018-99-119962

Published: 2018

Journal Articles

Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis

Mark B. Geyer, Meier Hsu, Sean M. Devlin, Martin S. Tallman, Dan Douer, Jae H. Park

Blood (2017) 129 (13): 1878–1881.

https://doi.org/10.1182/blood-2016-11-749507

Published: 2017

Includes: Supplemental data

Journal Articles

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Blood (2017) 129 (13): 1763–1767.

https://doi.org/10.1182/blood-2016-10-747170

Published: 2017

Journal Articles

A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial

Jae H. Park, MD, Ellen K. Ritchie, MD, Arati V. Rao, Sean Devlin, PhD, Meier Hsu, MS, Talal T Khawaja, B.S., Bridget A O'Donnell, B.S., Maria I Cazacu, B.S., Diane M Stopka, MS, Martin S. Tallman, MD, Dan Douer, MD

Blood (2016) 128 (22): 1629.

https://doi.org/10.1182/blood.V128.22.1629.1629

Published: 2016

Journal Articles

Impact of Treatment Center Characteristics on Early Death Rates in Patients with Newly Diagnosed Acute Promyelocytic Leukemia: Analysis of Data from the SEER Program

Jae H. Park, MD, Sean Devlin, PhD, Charles Lynch, Ann Schwartz, Theresa Keegan, PhD MS, Lou Gonsalves, Kim Hermit, MStat, Michael Green, Dan Douer, MD, Martin S. Tallman, MD

Blood (2016) 128 (22): 4008.

https://doi.org/10.1182/blood.V128.22.4008.4008

Published: 2016

Journal Articles

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Blood (2016) 128 (22): 5109.

https://doi.org/10.1182/blood.V128.22.5109.5109

Published: 2016

Journal Articles

Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population

Gary J Schiller, MD, Lloyd E. Damon, MD, Wendy Stock, MD, Steven E Coutre, MD, Pamela Hsu, Lucy Prasad, Dan Douer, MD

Blood (2015) 126 (23): 1291.

https://doi.org/10.1182/blood.V126.23.1291.1291

Published: 2015

NARROW

Novel Nilotinib Tablet Formulation: Pharmacokinetic Characterization and Effects of Food

Updated Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Peg-Asparaginase in the Era of Novel Agents

Updated Comparison of Outcomes in Hispanic and Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen in the Era of Novel Agents

Updated Outcomes of the University of Southern California (USC) ALL Frontline Regimen (based on CCG-1882) after Protocol Modification in the Era of Novel Agents in Ph-Negative ALL Patients

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

An Update on Outcomes Using the USC ALL Frontline Regimen (based on CCG-1882) after Further Modification of Protocol in the Era of Novel Agents in Ph-Negative ALL Patients; A Retrospective Study

Research and Care Networks in Acute Leukemia As a Model for Global Healthcare Collaboration

Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Pegaspargase in the Era of Novel Agents; A Retrospective Study

How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Acute Lymphocytic Leukemia in the Latin American Population

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Clinical, Cytogenetic and Immunophenotype Distribution of Adult Acute Lymphoblastic Leukemia Among Latinos — a Report from a Large Single Institution Cohort in Southern California

Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial

Impact of Treatment Center Characteristics on Early Death Rates in Patients with Newly Diagnosed Acute Promyelocytic Leukemia: Analysis of Data from the SEER Program

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only